Clinical Trials Industry News More

31. Æterna Zentaris Announces Positive Results For Phase 2 Study With LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 In Endometrial Cancer 11/30/2009
    Æterna Zentaris Inc. (the "Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, recently announced positive efficacy data from a Phase 2 study with its targeted cytotoxic peptide conjugate, AEZS-108 (formerly AN-152), in patients with advanced or recurrent endometrial cancer.
32. Scancell Selects PharmaNet Development Group For SCIB1 Clinical Trial 11/19/2009
    Scancell Holdings Plc, (PLUS:SCLP), the parent company of Scancell Limited (‘Scancell’), the developer of innovative therapeutic cancer vaccines, is pleased to announce that it expects to commence its Phase I/II clinical trial with SCIB in the first half of 2010.
33. Higher Dose of Merck's COZAAR (Losartan Potassium Tablets) Significantly Reduced Deaths and Hospitalizations Due to Heart Failure In Investigational Study 11/19/2009
    In an investigational study, Merck's medicine COZAAR (losartan potassium tablets) 150 mg, administered once daily, significantly reduced the risk of all-cause death or hospitalization due to heart failure compared to a lower 50 mg once daily dose of COZAAR.
34. TRIN Pharma Starts Phase I Clinical Trial Of TRIN 2755 In Solid Tumors 11/12/2009

    TRIN Pharma GmbH, specializing in the development of small molecule drugs for tumor treatment, announced today that BfArM, the German regulatory authority, has approved the start of a Phase I clinical trial of TRIN 2755 in solid tumors.

35. Homogeneous Fluorescence-Based Assay For Detecting Intracellular Calcium Mobilisation 11/12/2009
    Amsbio's Screen Quest Calcium Assay kit provides a homogeneous fluorescence-based assay for detecting intracellular calcium mobilisation across a broad spectrum of biological targets.
36. Human Genome Sciences And Glaxosmithkline Announce Positive Results In Second Of Two Phase 3 Trials Of Benlysta™ In Systemic Lupus Erythematosus 11/5/2009
    Human Genome Sciences, Inc. and GlaxoSmithKline PLC (GSK) recently announced that BENLYSTA (belimumab) met the primary endpoint in BLISS-76, the second of two pivotal Phase 3 trials in seropositive patients with systemic lupus erythematosus (SLE).
37. World's largest Malaria Vaccine Trial Now Underway In Seven African Countries 11/5/2009
    A pivotal efficacy trial of RTS,S, the world’s most clinically advanced malaria vaccine candidate, is now underway in seven African countries: Burkina Faso, Gabon, Ghana, Kenya, Malawi, Mozambique and Tanzania.
38. Millipore Scientist To Lead PDA Web Seminar On Innovative Testing Methods For Detecting Mycoplasma Contamination 10/28/2009
    Millipore Corporation, a leading provider of technologies, tools and services for the global life science industry, will lead a web-based seminar on detection of Mycoplasma and viral contamination, a subject of heightened interest in biopharmaceutical manufacturing.
39. Icagen Reports Top-Line Results Of Phase IIa Study Of Senicapoc In Exercise-Induced Asthma 10/28/2009
    Icagen, Inc. today reported that in a proof-of-concept, Phase IIa exercise-induced asthma study, senicapoc failed to demonstrate improvement in the primary study endpoints, including maximum decrease in FEV1, time to recovery of FEV1 after exercise and area under the FEV1 curve for sixty minutes.
40. Growing Threat Of Substandard And Counterfeit Medicines In Developing Countries Addressed By New USAID-USP Cooperative Agreement 10/28/2009
    With substandard and counterfeit versions of medicines intended to treat life-threatening diseases such as malaria, HIV/AIDS and tuberculosis posing a growing threat throughout the developing world, the U.S. Agency for International Development (USAID) and the U.S. Pharmacopeial Convention (USP) will expand their joint efforts to combat this menace by launching a new program over the next five years.